Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Metro Bank facing backlash over £60m pay plan for top execs - report

(Sharecast News) - Metro Bank is reportedly the latest London-listed company to face a backlash over its pay plans after drawing opposition to a proposal which could see top executives paid up to £60m apiece. According to Sky News, proxy adviser Institutional Shareholder Services (ISS) has told the high street lender's investors to vote against its remuneration policy and a Shareholder Value Alignment Plan (SVAP) at its annual meeting on 20 May.

ISS said in a report to clients - seen by Sky News - that the share award plan had the "potential to deliver outsized rewards".

"Performance is measured solely based on total shareholder return over a baseline value (80p for the May 2025 grant)," it said. "The use of share price targets, in general, may not necessarily reflect management performance.

"Despite the remuneration committee's explanations, overall, the company has not put forward a convincing case to support the SVAP."

The maximum potential payouts are dependent upon Metro Bank's stock hitting 437p - almost four times the level at which it is currently trading.

A source close to Metro Bank told Sky that the maximum payouts would only be triggered if its performance hit key hurdles over a five-year period.

On Thursday, Metro Bank said in an update that it remained confident of meeting full-year guidance as it reported a "significant" increase in first-quarter underlying profit versus the second half of 2024.

The bank put the jump in profit down to structurally higher net interest margin, driven by continued asset rotation and deposit optimisation.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.